SuperworthGain Therapeutics market cap GANX
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $55M
- Highest close in our data
- $149.4M
- Dec 2025
Gain Therapeutics is worth $55M at the close on Oct 23, 2026, at $1.26 a share.
That is down 23% over the last year and down 33% over five years.
Its highest close in our data was $149.4M in Dec 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $55M | $55M | $114.8M | −52% |
| 2025 | $113.7M | $42.6M | $149.4M | +144% |
| 2024 | $46.7M | $19M | $68.9M | +11% |
| 2023 | $42.2M | $27.9M | $65.4M | +14% |
| 2022 | $37.2M | $31.7M | $63.1M | −42% |
| 2021 | $64.5M | $64.5M | $126.4M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Gain Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| GANXGain Therapeutics | $55M |
| ATNMActinium Pharmaceuticals | $47.8M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| NATRNatures Sunshine Products | $213.8M |
| ARVNArvinas | $477.3M |
| Peer median | $73.4M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Gain Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.